Table 3 Clinical advances in stem cell-based therapy in the last 5 years
From: Meniscus repair: up-to-date advances in stem cell-based therapy
Clinical indication | No. of patients | Mean age | Male:Female | BMI (kg/m2) | Cell source | Cell count | Administration route | Stimuli | Follow-up | Clinical outcome | Level of evidence | Year/References |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Avascular meniscal tear | 5 | 37 yr | 4:1 | 25 (median) | BMSCs | 1.0 × 106/cm2 | collagen scaffold | FGF-2 | 2 years | IKDC, Tegner–Lysholm score, ROM | 4 | 2107/[119] |
Complex degenerative tears of the medial meniscus | 5 | 48.2 yr | All male | 25.9 (mean) | SMSCs | 3.2–7.0 × 107 | Intra-articular injection | – | 2 years | Lysholm, KOOS, NRS | 4 | 2019/[120] |
Medial meniscus tear | 6 | 54 yr | 5:1 | 23 (mean) | SMSCs | 4.0 × 107 | Intra-articular injection | – | 1 year | Lysholm | 4 | 2021/[121] |
Medial and lateral meniscal and anterior cruciate ligament tears | 1 | 31 yr | Female | / | BMSCs and ADSCs | 500–5000 × 106 BMSCs, 1600–400 × 106 ADSCs | Intra-articular and intravenous injection | Platelet-rich plasma | 1 year | / | 5 | 2021/[122] |
Meniscectomy history | 17 | 36 yr | 13:4 | 27.1 (mean) | Peripheral blood MSCs | 2.0 × 107 | Polyurethane meniscal scaffolds | – | 1 year | Lysholm | 3 | 2019/[123] |